Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Lee, Samuel S; Roberts, Stuart K; Berak, Hanna; Dusheiko, Geoffrey M; Harley, Hugh A; Gane, Edward J; Husa, Petr; Horsmans, Yves; Hadziyannis, Stephanos J; Jenny Heathcote, E; Messinger, Diethelm; Tatsch, Fernando; Han, Kwang-Hyub; Ferenci, Peter

doi:10.1111/j.1478-3231.2012.02819.x

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Lee, Samuel S

;

Roberts, Stuart K

;

Berak, Hanna

;

Dusheiko, Geoffrey M

;

Ferenci, Peter

;et.al.

(2012) Liver International — Vol. 32, n° 8, p. 1270-1277 (2012)

Files

pdfdocument.pdf

Restricted Access
Adobe PDF
210.84 KB

Request a copy

Details

Authors

Lee, Samuel S
Author
Roberts, Stuart K
Author
Berak, Hanna
Author
Dusheiko, Geoffrey M
Author
Horsmans, YvesUCLouvain
Author
Ferenci, Peter
Author

Abstract

This study confirmed the safety and tolerability profile of peginterferon alfa-2a/ribavirin and identified patient subgroups at higher risk of dose reductions and discontinuations, thus allowing optimum management of AEs.

Affiliations

Citations

APA
Chicago
FWB

Lee, S. S., Roberts, S. K., Berak, H., Dusheiko, G. M., Harley, H. A., Gane, E. J., Husa, P., Horsmans, Y., Hadziyannis, S. J., Jenny Heathcote, E., Messinger, D., Tatsch, F., Han, K.-H., & Ferenci, P. (2012). Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver International, 32(8), 1270-1277. https://doi.org/10.1111/j.1478-3231.2012.02819.x (Original work published 2012)